Los puntos clave no están disponibles para este artículo en este momento.
The identification of oncogenic mutations in diffuse large B-cell lymphoma (DLBCL) has led to the development of drugs that target essential survival pathways, but whether targeting multiple survival pathways may be curative in DLBCL is unknown.
Melani et al. (Wed,) studied this question.